With a new FDA approval to rival Teva's Austedo, Neurocrine Biosciences’ Ingrezza is debuting in a treatment area with hundreds of millions of dollars of revenue potential. Late last week, the FDA ...
SAN DIEGO, Jan. 15, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of the first head-to-head data comparing vesicular monoamine transporter 2 (VMAT2) ...
INGREZZA showed higher rates of long-term treatment continuation and lower switching between medications compared to AUSTEDO XR (deutetrabenazine) in a real-world claims analysis among adults with ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Teva's first DTC campaign for tardive dyskinesia (TD) drug Austedo launches into a suddenly competitive TV ad space for the rare condition. It joins Neurocrine Biosciences' Ingrezza campaign that ...
Verywell Health on MSN
How is Huntington's disease treated?
Medically reviewed by Huma Sheikh, MD Key Takeaways The medications approved by the Food and Drug Administration (FDA) for ...
SAN DIEGO - Neurocrine Biosciences Inc. (NASDAQ:NBIX) presented real-world claims data today showing adults with tardive dyskinesia treated with Ingrezza demonstrated higher treatment continuation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results